-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Galecto, Inc gets an overall score of 1/5.
ISIN | US36322Q1076 |
---|---|
Exchange | NASDAQ |
CurrencyCode | USD |
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | 4M |
---|---|
PE Ratio | None |
Target Price | 8 |
Beta | 1.28 |
Dividend Yield | None |
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GLTO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025